Patents by Inventor Nathan V. LEE

Nathan V. LEE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230398119
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
    Type: Application
    Filed: April 26, 2023
    Publication date: December 14, 2023
    Inventors: Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI, Nathan V. LEE
  • Patent number: 11666574
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: June 6, 2023
    Assignee: Turning Point Therapeutics, Inc.
    Inventors: Wei Deng, Dayong Zhai, Laura Rodon, Brion W. Murray, Jingrong J. Cui, Nathan V. Lee
  • Publication number: 20210154198
    Abstract: The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with an inhibitor of MAPK/ERK kinase-1 and -2 (MEK1 and MEK2; MAP2K1 and MAP2K2), such as trametinib.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 27, 2021
    Inventors: Wei DENG, Dayong ZHAI, Laura RODON, Brion W. MURRAY, Jingrong J. CUI, Nathan V. LEE